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single-source exposure with C. botu-
linum type B in at least 3 IDUs; this 
implies that the heroin was obtained 
from a common source, where contam-
ination with C. botulinum spores may 
have been introduced when mixed with 
adulterants or diluted with substances 
such as dextrose or dyed paper. Skin 
popping (subcutaneous and intramus-
cular injection), which may increase 
the odds of wound botulism by a fac-
tor >15 (9), was used by all patients 
for drug delivery. This study conﬁ  rms 
previous observations that the duration 
of clinical symptoms before antitoxin 
administration affects the need for and 
duration of mechanical ventilation (10). 
Here, the time from hospital admission 
to antitoxin treatment ranged from 
several hours to 4 days and correlated 
with the mechanical ventilation inter-
val ranging from 0 days to 11 weeks. 
In addition, the extent of abscesses, 
which ranged from no abscesses to 
multiple abscesses, seems to affect 
clinical outcome. As soon as an index 
case of wound botulism in IDUs is di-
agnosed, a coordinated public health 
case-management effort, including 
hospitals, outpatient clinics, and infor-
mation centers for drug addicts, is man-
datory to alert the medical community 
and the drug users to consider wound 
botulism if typical symptoms occur and 
to enable the prompt administration of 
antitoxin. Obtaining tissue samples or 
abscess ﬂ  uid for culture and molecular 
epidemiologic studies of C. botulinum 
isolates is necessary to facilitate iden-
tiﬁ  cation of the source of the contami-
nated heroin.
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Multidrug-Resistant 
Acinetobacter 
baumannii
To the Editor: In the January 
2007 issue of Emerging Infectious 
Diseases, Sunenshine et al. (1) de-
scribed their ﬁ   nding of an indepen-
dent association between patients with 
multidrug-resistant (MDR) Acineto-
bacter infection and increased hospital 
and intensive care unit (ICU) length of 
stay compared with that for patients 
with antimicrobial drug–susceptible 
Acinetobacter infection. The authors 
did not, however, ﬁ  nd a statistically 
signiﬁ  cant difference in mortality rates 
between the 2 groups of patients.
Acinetobacter infections fre-
quently occur in severely ill ICU pa-
tients with other chronic illnesses or 
prolonged hospitalizations. We ana-
lyzed data for 27 neutropenic cancer 
patients with A. baumannii–associated 
bacteremia (15 with MDR and 12 with 
drug-susceptible A. baumannii infec-
tions) but no other chronic illness. We 
considered A. baumannii strains to be 
MDR if they were resistant to amika-
cin, meropenem, and ciproﬂ  oxacin. 
Univariate analysis (Epi Info 2000; 
Centers for Disease Control and Pre-
vention, Atlanta, GA, USA) showed 
that most of the bacteremic episodes 
were associated with certain risk fac-
tors, such as catheter insertion, neu-
tropenia, acute leukemia, and pre-
vious prophylactic treatment with 
quinolones or therapeutic treatment 
with cephalosporins or carbapenems 
(meropenem or imipenem) (Table).LETTERS
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Septic shock developed in 4 
(14.8%) of the 27 neutropenic patients 
with  A. baumannii–associated bac-
teremia, and 2 (7.4%) of the 27 died 
(Table). However, we did not ﬁ  nd a 
statistically signiﬁ  cant  association 
between death among patients with 
bacteremia caused by MDR A. bau-
manni (1 death) compared with death 
among those with bacteremia caused 
by A. baumannii strains susceptible to 
the carbapenems, ciproﬂ  oxacin,  and 
amikacin (1 death) (Table). This ﬁ  nd-
ing is similar to that described by Su-
nenshine et al. (1) in the general ICU 
population and in neutropenic cancer 
patients with bacteremia; however, 
multivariate analysis was not conduct-
ed to control for severity of illness and 
coexisting illness. In conclusion, neu-
tropenic cancer patients with bactere-
mia due to MDR A. baumannii infec-
tion do not appear to be at increased 
risk for death compared with patients 
with bacteremia due to antimicrobial 
drug–susceptible A. baumannii.
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Serogroup X in 
Meningococcal 
Disease, 
Western Kenya 
To the Editor: Although >12 
different serogroups of Neisseria 
meningitidis exist, most disease out-
breaks across the African meningitis 
epidemic belt are caused by serogroup 
A and, less frequently, by serogroups 
C and W135 (1). N. meningitidis se-
rogroup X was ﬁ  rst described in the 
1960s and has been found to cause a 
few cases of invasive disease across 
North America, Europe, and Africa 
(2). In Africa, small serogroup X out-
breaks have been described in Ghana 
(9 cases over a 2-year period) and in 
Niger (134 cases between 1995 and 
2000) (3,4). In 2006, however, 51% of 
1,139 conﬁ  rmed cases of meningococ-
cal meningitis in Niger were found to 
be caused by serogroup X (5). Before 
the 2005-06 meningococcal epidemic 
season, no published reports had de-
scribed serogroup X isolates in East 
Africa. We report the involvement 
of N. meningitidis serogroup X in an 
outbreak of meningococcal disease in 
Western Kenya.
In January 2006, the Ministry of 
Health of Kenya and Médecins sans 
Frontières were notiﬁ  ed of a suspect-
ed meningococcal disease outbreak in 
West Pokot District, bordering Ugan-
da, in Western Kenya. On the basis of 
the initial outbreak investigation, the 
outbreak was assessed to have begun 
in late December 2005. Subsequent 
active surveillance, using the same 
clinical case deﬁ  nition of sudden fever 
onset with stiff neck, altered mental 
status, or both, showed 74 suspected 
cases through mid-March 2006, with 
a case-fatality rate of 20%. No cases 
were reported after March 2006.
Over the course of the outbreak, 
cerebrospinal ﬂ  uid samples were ob-
tained from 18 patients. Due to low 
population density, poor access to 
seminomadic populations, and the 
Table. Risk factors and outcome for 27 neutropenic cancer patients with bacteremia 
due to multidrug-resistant (MDR) or drug-susceptible Acinetobacter baumannii infection
Characteristic
All patients, 
no. (%) 
(N = 27)
Patients with  
drug-susceptible
A. baumannii,  
no. (%)* 
(n = 12, 44%)
Patients with 
MDR
A. baumannii,
no. (%)* 
(n = 15, 56%)
Risk for bacteremia 
Central venous catheter 19 (70.4) 9 (75.0) 10 (66.7)
Acute leukemia 11 (40.7) 6 (50.0) 5 (33.3)
Previous prophylaxis with 
quinolones 14 (51.9) 8 (66.7) 6 (40.0)
Previous therapeutic treatment 
with cephalosporins 15 (55.6) 8 (66.7) 7 (46.7)
Previous therapeutic treatment 
with carbapenems 8 (29.6) 4 (33.3) 4 (26.7)
Outcome
Septic shock  4 (14.8) 2 (16.7) 2 (13.3)
Death 2 (7.4) 1 (8.3) 1 (6.7)
*Insignificant difference between patients with drug-susceptible infection and those with MDR 
infection (p<0.05 by univariate analysis). 
Letters
Letters commenting on recent articles 
as well as letters reporting cases, out-
breaks, or original research are wel-
come. Letters commenting on articles 
should contain no more than 300 
words and 5 references; they are more 
likely to be published if submitted 
within 4 weeks of the original article’s 
publication. Letters reporting cases, 
outbreaks, or original research should 
contain no more than 800 words and 
10 references. They may have one 
Figure or Table and should not be di-
vided into sections. All letters should 
contain material not previously pub-
lished and include a word count.